Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

AL amyloidosis

Other Names for this Disease
  • Amyloidosis AL
  • Amyloidosis primary systemic
  • Light chain amyloidosis
  • Primary AL amyloidosis
  • Primary amyloidosis (Formerly)
More Names
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


ORDR-Sponsored Conferences

  • RDCRN 3rd Conference on Clinical Research for Rare Diseases, Tuesday, October 02, 2012
    Location: Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Rockville, MD
    Description: Clinical research in rare diseases presents a number of challenges and unique issues that are not usually considered in the training of clinical investigators through existing training programs. Goals of the conference include: direct instruction of trainees and new investigators in rare disease research methodology; development of a reusable curriculum/syllabus on rare disease research methodology; and stimulation of ideas regarding the unique issues facing investigators engaged in the study of rare diseases.

  • VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010): Global Approach to Accessibility in Rare Diseases, Orphan Drugs and Neglected Diseases , Thursday, March 18, 2010 - Saturday, March 20, 2010
    Location: Palais Rouge Convention Center, Palermo, Buenos Aires, Argentina
    Description: For the first time, the VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010) was convened in the southern hemisphere in agreement with its aim of globalization of rare diseases research and orphan products development activities.

  • Systemic Amyloidosis Focus Group Workshop, Tuesday, June 20, 2006
    Location: Marriott Hotel and Conference Center, Bethesda, MD
    Description: The amyloidoses contain a large group of disorders that have in common the presence of insoluble protein deposits in tissues. Most amyloidoses are diffuse, that is, multisystemic. Treatments vary for any one amyloidosis, and treatments range from anti-inflammatory treatment, dialysis, or chemotherapy followed by stem cell replacement to reduce the levels of monoclonal immunoglobulin to organ transplantation, particularly liver and kidneys. ORD and a broad-based NIH planning group developed steps needed for a small, comprehensive conference with invited experts to identify scientific needs and opportunities and to provide input into developing a draft research plan. Participants considered recommendations from the scientific conferences held in 2005 and provided advice on a comprehensive, detailed research and treatment plan for the amyloidoses.